US-based mutual insurance company Sham has helped Alizé Pharma, a France-based metabolic diseases and cancer group, raise €3.3m ($4.1m).

The round was joined by Octalfa, a family office, Cema Inc, a Canada-based holding company, and Thierry Abribat, Alizé’s founder and president. In 2009 Sham, Octalfa and Cema invested in a €3m round, taking the amount raised by Alizé since its founding in 2007 to €4.8m.

Alizé Pharma owns five families of patents, with a total of 34 patents and patent…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?